Hanseatic Management Services Inc. Boosts Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Hanseatic Management Services Inc. boosted its position in Natera, Inc. (NASDAQ:NTRA) by 23.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 891 shares of the medical research company’s stock after buying an additional 170 shares during the quarter. Hanseatic Management Services Inc.’s holdings in Natera were worth $113,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. M&G PLC lifted its holdings in Natera by 3.0% during the third quarter. M&G PLC now owns 104,302 shares of the medical research company’s stock valued at $13,246,000 after purchasing an additional 3,001 shares during the last quarter. Marks Group Wealth Management Inc bought a new position in shares of Natera in the third quarter valued at approximately $206,000. Leeward Financial Partners LLC purchased a new position in shares of Natera during the 3rd quarter valued at $215,000. QRG Capital Management Inc. bought a new position in shares of Natera in the third quarter worth $671,000. Finally, Harbor Capital Advisors Inc. raised its position in shares of Natera by 261.2% in the third quarter. Harbor Capital Advisors Inc. now owns 18,124 shares of the medical research company’s stock worth $2,301,000 after buying an additional 13,106 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Michael Burkes Brophy sold 1,866 shares of Natera stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $126.45, for a total transaction of $235,955.70. Following the sale, the chief financial officer now owns 68,851 shares of the company’s stock, valued at approximately $8,706,208.95. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Jonathan Sheena sold 2,700 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $113.82, for a total value of $307,314.00. Following the completion of the sale, the insider now owns 299,441 shares in the company, valued at approximately $34,082,374.62. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 1,866 shares of the company’s stock in a transaction dated Thursday, October 31st. The stock was sold at an average price of $126.45, for a total transaction of $235,955.70. Following the completion of the transaction, the chief financial officer now owns 68,851 shares in the company, valued at $8,706,208.95. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,164 shares of company stock valued at $6,157,291. 7.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on NTRA shares. Canaccord Genuity Group boosted their target price on Natera from $145.00 to $150.00 and gave the stock a “buy” rating in a research report on Tuesday, October 29th. Sanford C. Bernstein upped their price objective on Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. BTIG Research lifted their price target on shares of Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. TD Cowen raised their price target on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, Robert W. Baird boosted their price objective on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $125.69.

Natera Trading Up 2.1 %

NASDAQ:NTRA opened at $126.97 on Thursday. Natera, Inc. has a 52 week low of $40.61 and a 52 week high of $133.54. The stock has a market cap of $15.70 billion, a price-to-earnings ratio of -51.82 and a beta of 1.53. The company’s 50 day moving average price is $123.75 and its 200-day moving average price is $113.16. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. The firm had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The business’s revenue for the quarter was up 58.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.97) earnings per share. On average, equities research analysts forecast that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.